Tuesday, 19 Mar 2019

You are here

Apremilast Continues to Look Good in Behcet's Disease

The 2018 American Academy of Dermatology (AAD) Annual Meeting features recent findings of a phase III trial of apremilast in active Behçet’s Disease, showing significant reductions in oral ulcers at week 12 for those treated with apremilast 30 mg twice daily.

The RELIEF trial studied 207 patients who were randomized to apremilast 30 mg BID or placebo. The trial’s primary endpoint was the area under the curve (AUC) for the number of oral ulcers at week 12.

The AUC was significantly for apremilast versus placebo (129.5 vs. 222.1; P<0.0001). Significant improvements were also seen with apremilast in multiple secondary endpoints, including oral ulcer pain (P<0.0001), overall disease activity (Behçet’s Syndrome Activity Score: P<0.0001; Behçet’s Disease Current Activity Index: P=0.0335) and quality of life (P=0.0003).

Diarrhea was the most frequent adverse event (41.3 percent with apremilast, 19.4 percent for placebo). Otherwise the safety profile was consistent with the known safety profile of apremilast.

Celgene intends to submit its supplemental New Drug Applications for apremilast in active Behçet’s Disease with oral ulcers in the U.S. in the second half of this year.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CRA Position Statement on Medical Cannabis Use

Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.

Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.

Senate Drills Drug Makers Over Price

Reuters reported that today, the US Senate Finance Committee met to question the executives from seven US pharmaceutical companies on the rising price drugs in America. 

Canadian Vaccination Guidelines for the Immunosuppressed

A multidisciplinary Canadian task force has developed guidelines for vaccination in patients receiving immunosuppressive therapies, based on the evidence that immunosuppressive use in immune-mediated disease may be  associated with an elevated risk of infections. 

No Difference in Oral or IV Antibiotics for Bone & Joint Infections

Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.

There is considerable discussion whether complex bone and joint infections must be managed with prolonged intravenous antibiotics or if oral antibiotic therapy may suffice. 

2019: the Year of Price Hikes

In 2019 there have been numerous reports of higher drug pricing for many drugs.  Yesterday it was reported that the price of insulin drugs have more than doubled from 2012 to 2016.

Reuters reports that in the United States, the pricing on more than 250 prescription drugs have gone up.